Home / Knowledge Centre /
Article

Enabling Emerging Biotechs with Supply with Care

Emerging biotech companies were responsible for 65% of the molecules in the research and development pipeline, compared to less than 50% in 2016. Despite their explosive growth, the sector faces challenges ranging from cost pressures and supply chain disruptions to regulatory changes and geopolitical instability.

In a recent Almac Clinical Services-sponsored Biopharma Dive webcast, “Enabling Emerging Biotechs with Supply With Care,” Paul O’Connor, Global Vice President of Quality and Richard Segiel, Vice President of Business Development North America, highlighted the role that strategic partnerships and technological advancements can play in overcoming the obstacles faced by emerging biotech companies.

View Resource

Please complete this form to view the Article

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies